Nuvation Bio Future Growth
Future criteria checks 0/6
Nuvation Bio's earnings are forecast to decline at 7.8% per annum while its annual revenue is expected to grow at 58% per year. EPS is expected to grow by 4% per annum.
Key information
-7.8%
Earnings growth rate
4.0%
EPS growth rate
| Pharmaceuticals earnings growth | 23.4% |
| Revenue growth rate | 58.0% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 17 Apr 2024 |
Recent future growth updates
Recent updates
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Mar 31Nuvation: Cash Is King, Science Is An Afterthought
Oct 03We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Sep 14
Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit
Feb 14We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely
Feb 10We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Nov 09Nuvation Bio GAAP EPS of -$0.12 beats by $0.02
Nov 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 19 | -164 | N/A | N/A | 3 |
| 12/31/2025 | 1 | -163 | N/A | N/A | 4 |
| 12/31/2024 | N/A | -101 | N/A | N/A | 6 |
| 12/31/2023 | N/A | -76 | -68 | -68 | N/A |
| 9/30/2023 | N/A | -83 | -69 | -69 | N/A |
| 6/30/2023 | N/A | -90 | -81 | -81 | N/A |
| 3/31/2023 | N/A | -105 | -91 | -91 | N/A |
| 12/31/2022 | N/A | -104 | -96 | -96 | N/A |
| 9/30/2022 | N/A | -108 | -104 | -103 | N/A |
| 6/30/2022 | N/A | -103 | -89 | -88 | N/A |
| 3/31/2022 | N/A | -88 | -79 | -78 | N/A |
| 12/31/2021 | N/A | -87 | -68 | -68 | N/A |
| 9/30/2021 | N/A | -75 | -58 | -58 | N/A |
| 6/30/2021 | N/A | -64 | -53 | -53 | N/A |
| 3/31/2021 | N/A | -53 | -43 | -43 | N/A |
| 12/31/2020 | N/A | -42 | -37 | -37 | N/A |
| 9/30/2020 | N/A | -38 | -33 | -33 | N/A |
| 6/30/2020 | N/A | -32 | -33 | -32 | N/A |
| 3/31/2020 | N/A | -33 | -30 | -29 | N/A |
| 12/31/2019 | N/A | -34 | -25 | -24 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NUVB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NUVB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NUVB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NUVB is forecast to have no revenue next year.
High Growth Revenue: NUVB is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NUVB's Return on Equity is forecast to be high in 3 years time